Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021
The global biomarkers market is estimated to reach USD 53.34 Billion by 2021 from USD 27.95 Billion in 2016, at a CAGR of 13.8% from 2016 to 2021. Growth in the global biomarkers industry is mainly driven by factors such as increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, increasing number of CROs and low cost of clinical trials in developing countries, the high prevalence of cancer, and new initiatives for research. On the other hand, high capital investments and low cost-benefit ratio, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection and storage are the major factors restraining the growth of this market.
The global cancer biomarkers market is accounted for USD 10.31 billion in 2016 and is expected to grow at a CAGR of 12.2% to USD 20.48 billion by 2022 during the forecast period. Due to the growing prevalence of cancer worldwide, the use of cancer biomarkers has increased significantly in recent years, providing opportunities for improving the management of cancer patients by enhancing detection and efficacy of treatment. Cancer biomarkers are present in tumor tissues or sera and encompass a wide variety of molecules, including DNA, mRNA, transcription factors, cell surface receptors, and secreted proteins. These biomarkers can be used for the prognosis and predicting the natural course of a tumor. They can also help doctors decide which patients are likely to respond to a given drug (prediction) and at what dosage it might be most effective (pharmacodynamics).
See how this study impacted revenues for other players in Biomarkers Market
Clients Problem Statement
Our client, a leading provider of analytical laboratory instruments and software, wanted information about
The global market for various segments including biomarker instruments market, disease indication and consumables market by application and by assay kits & reagents
The bifurcation of the total biomarker market in drug discovery and development and use of diagnostics. The diagnostics segment was required to be further segmented into research as well as clinical use
Detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
Market share analysis by key players in the mass spectroscopy segment 
MnM Approach
MnM started by identifying the key technologies used in biomarker identification and profiling. Later, MnM identified key applications and diseases whereof each of these technologies is used. MnM interviewed product suppliers and potential customers/end-use industries to understand their unmet needs, possible use cases, and the benefits of these technologies and what they looked for in a technology partner.
This helped our client assess the market potential across various application areas, including clinical diagnostics, research, and drug discovery, among others. MnM also helped the client build an understanding of the competitive landscape, varying business models, and strategies of players in the biomarkers market. This helped them devise a differentiated product offering and forge suitable alliances to help them win in this market.
Revenue Impact (RI)
Our analysis helped the client tap into a USD ~51.5 billion biomarkers market globally, with a serviceable market of USD 5.2 billion due to our recommendations.
See how this study impacted revenues for other players in Biomarkers Market
Clients Problem Statement
Helped a global leader in analytical laboratory instruments and software market in identifying ~USD 5.2 billion revenue potential by tapping into biomarker diagnostics and research market globally.
MnM Approach
MNM started by identifying key technologies used in biomarker identification and profiling. Later, MNM started identifying key applications and diseases where of each of these technologies is used. For this, MNM interviewed a host of product suppliers and potential customers/end-use industries to understand their unmet needs, possible use cases & benefits from these technologies and what they looked for in a technology partner. This helped our client to assess the market potential across various application areas including clinical diagnostics, research, drug discovery among others. Further, MNM also helped the client build an understanding of the competitive landscape, varying business models & strategies of different players in biomarker technology market. This helped them to devise a differentiated product offering & forge suitable alliance to help them win in this market.
Revenue Impact (RI)
Our work resulted in the client tapping into a USD ~51.5 billion Biomarker technologies market globally, with a serviceable market of USD 5.2 billion globally from our recommendations.
By product, consumables segment is expected to witness growth in the biomarkers market during the forecast period.
Based on product, the biomarkers market is segmented into consumables, services, and software. The consumables segment accounted for the largest share of the global biomarkers market in 2016, primarily due to the increasing use of reagent kits and assays for biomarker testing and the higher frequency of purchase of consumables. Although the price of consumables is lower than that of screening and automation instruments, consumables have a higher share in this market owing to their larger sales volume. As such, growth in the overall biomarkers market will be the most important driver for this product segment. Furthermore, the introduction of singleplex platforms, multiplex platforms, and automated ELISA systems that require assay kits is expected to aid the growth of this product segment.
By type, efficacy biomarkers segment is expected to grow at the highest CAGR during the forecast period.
Based on type, the biomarkers market is segmented into safety, efficacy, and validation biomarkers. The efficacy biomarkers segment is further classified into predictive, surrogate, pharmacodynamic, and prognostic biomarkers.
In 2016, the safety biomarkers segment accounted for the largest share of the biomarkers market. However, the efficacy biomarkers segment is estimated to register the highest CAGR during the forecast period. The efficacy biomarkers segment is expected to register the highest growth during the forecast period, primarily due to the wide range of products available in the market and the growing adoption of these biomarkers for various applications. PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Netherlands), and Enzo Biochem, Inc. (U.S.) are some of the major players operating in this market segment
By application, personalized medicine segment is expected to grow at the highest CAGR during the forecast period.
Biomarkers are mainly used in diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications (DNA fingerprinting, ecotoxicology, and forensics). Use of biomarkers for the diagnosis of multiple diseases, including cancer, cardiovascular disorders, and neurological disorders is increasing. This is the major factor that drives the growth of diagnostic segment of the biomarker market. However, with growing demand for custom-designed treatment plans for diseases like cancer, the personalized medicine segment is expected to witness the highest growth in the forecast period
By disease indication, cardiovascular disorder segment is expected to grow at the highest CAGR during the forecast period
Biomarkers are widely used in the diagnosis and management of multiple diseases. Physiological levels of biomarkers also change upon the administration of drugs. The analysis of multiple biomarkers helps clinicians make important decisions about the diagnosis, disease stage, therapy plan, and prognosis in patients.
Based on the disease indication, this report is segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other disease indications. Cancer forms the largest segment primarily due to the increasing prevalence of cancer globally and the growing application of biomarkers in cancer diagnostics
Cardiac biomarker tests play a significant role in detecting the presence of diseases and evaluating their severity so that the appropriate therapies can be initiated. These biomarkers are classified as biomarkers of myocardial injury, biomarkers of hemodynamic stress, and inflammatory and prognostic biomarkers. Troponin is a prominent biomarker used for the diagnosis of myocardial infarction.
New biomarkers for cardiovascular disorders are being developed. Natriuretic peptides (ANP, BNP, CNP, and related peptides), endothelins, cardiac troponins (cTnI and cTnT), collagen propeptides, Fas (APO-1), isoprostanes, and alterations of the hypophysial-adrenal axis are some examples of biomarkers that have been identified for heart failure
In 2016, North America accounted for the largest share of the biomarkers market.
In 2016, North America accounted for the largest share of this market, followed by Europe. The biomarkers market in North America is primarily driven by increasing R&D and growing use of biomarkers in personalized medicine and drug discovery and development.
The increase in R&D spending for biomarker research and development activities is the key factor responsible for the growth of the biomarkers market in North America. Moreover, North America has a well-established pharmaceuticals sector and dominates the biomarkers market due to the increasing demand of the aging population for the diagnosis and treatment of age-related diseases. In addition, the higher adoption rate of biomarkers for disease diagnostics, majorly in cancer diagnosis, is driving the growth of the biomarkers market in North America.
Market Dynamics
Driver:Increasing diagnostic applications of biomarkers
Biomarkers are prominently used in application areas such as personalized medicines, companion diagnostics, and other diagnostic areas including drug discovery and development and disease risk assessment. These increasing diagnostic applications of biomarkers are expected to drive market growth in the coming years.
Biomarkers play a key role in personalized medicine, with applications including diagnosis, prognosis, and selection of targeted therapies. Over the years, personalized medicine has gained recognition due to the various limitations of standard diagnosis and treatment procedures. Many areas of medicine, from cancer to immunological disorders, are moving towards tailored treatment for individual patients based on their genetic signatures and clinical characteristics.
Companion diagnostics and biomarkers have become increasingly relevant in the practice of medicine, leading to improved diagnosis, treatment, and monitoring across a number of disease areas. It can be used to identify patients likely to respond well to certain drugs or treatment options. These diagnostics are often used in conjunction with a specific drug. For instance, the Trofile assay is used to determine trophism of the human immunodeficiency virus (HIV) and the likelihood of a patient responding well to the prescription of Selzentry. For the development of companion diagnostics, pharmaceutical companies are often partners of choice. Pharmaceutical companies have a growing interest in the development of companion diagnostics and may be willing partners in their development. For instance, in July 2013, Thermo Fisher Scientific, Inc. (U.S.) signed a collaboration agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for the development of companion diagnostics.
Restraint: High capital investments and low cost-benefit ratio
Validating biomarkers is a lengthy process owing to the inconsistency in its performance in disease diagnosis. Due to this, the validation process becomes time-consuming (approximately 15 years together with the time needed for FDA approval) as well as expensive (often exceeding USD 1 billion)
Huge capital investments are required for the discovery, development, and validation of biomarkers. This weighs down the growth of the biomarkers market and other related markets such as diagnostics (in vitro diagnostics or companion diagnostics) and personalized medicines. The discovery of candidate biomarkers far outpaces the current ability to validate them. This is a major challenge faced by the personalized medicines market. Also, due to the high drug attrition rate in clinical trials (with almost 30% of drugs failing in phase III), diagnostics manufacturers face enormous financial challenges. To pass an IVD from the regulators, manufacturers need successful phase III clinical trials, which are in turn dependent on well-validated biomarker tests. Huge investments are required to run clinical trials and address stringent regulatory requirements, which not only affect the ability of small companies to develop biomarkers but also severely affect innovation. Hence, along with high capital investments, the low cost-benefit ratio also hinders market growth.
Opportunity: Emerging Economies
Healthcare expenditure is a critical growth driver for the biomarkers market. According to estimates from the World Bank, the global healthcare spending increased at a CAGR of 7.45% from 2003 to 2012. Growth in the healthcare expenditure in emerging economies across Asia and the RoW has been outpacing those of North America and Europe. The growth rates of the healthcare expenditure in Asia and the RoW between 2003 and 2012 were 11.57% and 14.57%, respectively. Rapid growth in healthcare expenditure in these emerging geographies provides more scope for R&D in the biomarkers market. Furthermore, the increasing burden of diseases, coupled with the larger population in these geographic segments, is an important consideration for higher growth expectations in these regions. Also, the growth in the number of hospitals in these regions offers important growth opportunities for biomarkers manufacturers.
Challenge: Proving the clinical validity in biomarker-based tests
The biomarker validation process includes evaluation of assays or measurement of performance characteristics such as sensitivity, specificity, and reproducibility. Validation is critical for establishing biomarkers as reliable tools to support development, medical care, and biopharma investment decisions. However, the high costs involved in biomarker validation are a major concern for companies, especially small organizations. Furthermore, factors such as the inherent variability in biomarker levels and molecular heterogeneity pose additional challenges in the biomarker validation process. Another challenge is the length of time required for assay development due to which the ability to develop assays does not keep pace with the ability to generate biomarkers.
Scope of the Report
|
Report Metric |
Details |
|
Market size available for years |
20142021 |
|
Base year considered |
2015 |
|
Forecast period |
2062021 |
|
Forecast units |
Million (USD) |
|
Segments covered |
Product, Type, application, disease indication, and region |
|
Geographies covered |
North America (US and Canada), Europe, APAC (China, Japan and Rest of Asia), and the RoW |
|
Companies covered |
Qiagen N.V., Perkinelmer, Inc., Merck Millipore, Bio-Rad Laboratories, Inc., Enzo Biochem, Inc., EKF Diagnostics Holdings, Inc., Meso Scale Diagnostics, LLC., Biosims Technologies Sas, Cisbio Bioassays, Signosis, Inc. |
Key Market Players
Qiagen N.V., Perkinelmer, Inc., Merck Millipore, Bio-Rad Laboratories, Inc., Enzo Biochem, Inc., EKF Diagnostics Holdings, Inc., Meso Scale Diagnostics, LLC., Biosims Technologies Sas, Cisbio Bioassays, Signosis, Inc.
Recent Developments
Critical questions the report answers:
- Who are the major market players in the market?
- What are the regional growth trends and the largest revenue-generating regions for market?
- What are the major drivers and challenges in the market?
- What are the major product segments in the market?
- Who are the major end users of biomarker products?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table Of Contents
1 Introduction (Page No. - 13)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered in the Report
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. - 17)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.2.1 Key Data From Secondary Sources
2.2.2 Key Data From Primary Sources
2.3 Market Rank Estimation
2.4 Key Industry Insights
2.5 Assumptions for the Study
3 Executive Summary (Page No. - 25)
4 Premium Insights (Page No. - 29)
4.1 Biomarkers: Market Overview
4.2 Geographic Analysis: Biomarkers Market, By Product (2016)
4.3 Biomarkers Market, By Type, 2016 Vs. 2021
4.4 Biomarkers Market Size, By Application, 2016 Vs. 2021
4.5 Biomarkers Market, By Disease Indication, 2016 Vs. 2021
4.6 Biomarkers Market: Geographic Growth Opportunities
4.7 Life Cycle Analysis, By Region, 2016
5 Market Overview (Page No. - 34)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Diagnostic Applications of Biomarkers
5.2.1.1.1 Personalized Medicine
5.2.1.1.2 Companion Diagnostics
5.2.1.2 Increasing R&D Funding for Pharma and Biotech Companies
5.2.1.3 Increasing Number of Cros and Low Cost of Clinical Trials in Developing Countries
5.2.1.4 High Prevalence of Cancer
5.2.1.5 New Initiatives for Biomarker Research
5.2.2 Restraints
5.2.2.1 High Capital Investments and Low Cost-Benefit Ratio
5.2.2.2 Poorly Suited Regulatory and Reimbursement Systems
5.2.2.3 Technical Issues Related To Sample Collection and Storage
5.2.3 Opportunities
5.2.3.1 Emerging Economies
5.2.4 Challenges
5.2.4.1 Proving the Clinical Validity in Biomarker-Based Tests
6 Biomarkers Market, By Product (Page No. - 43)
6.1 Introduction
6.2 Consumables
6.3 Services
6.4 Software
7 Biomarkers Market, By Type (Page No. - 50)
7.1 Introduction
7.2 Safety Biomarkers
7.3 Efficacy Biomarkers
7.3.1 Predictive Biomarkers
7.3.2 Surrogate Biomarkers
7.3.3 Pharmacodynamic Biomarkers
7.3.4 Prognostic Biomarkers
7.4 Validation Biomarkers
8 Biomarkers Market, By Application (Page No. - 63)
8.1 Introduction
8.2 Diagnostics
8.3 Drug Discovery and Development
8.4 Personalized Medicine
8.5 Disease Risk Assessment
8.6 Other Applications
9 Biomarkers Market, By Disease Indication (Page No. - 76)
9.1 Introduction
9.2 Cancer
9.3 Cardiovascular Disorders
9.4 Neurological Disorders
9.5 Immunological Disorders
9.6 Other Diseases
10 Biomarkers Market, By Region (Page No. - 89)
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 Uk
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe (Roe)
10.4 Asia
10.4.1 China
10.4.2 Japan
10.4.3 Rest of Asia
10.5 Rest of the World (Row)
10.3.1 Latin America
10.3.2 Middle East & Africa
11 Competitive Landscape (Page No. - 118)
11.1 Overview
11.2 Competitive Situation and Trends
11.2.1 Product Launches
11.2.2 Collaborations, Partnerships, and Agreements
11.2.3 Acquisitions
11.2.4 Other Developments
11.3 Leading Players in the Biomarkers Market
12 Company Profiles (Page No. - 124)
(Overview, Products and Services, Financials, Strategy & Development)*
*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.
12.2 Perkinelmer, Inc.
12.3 Merck Millipore
12.4 Bio-Rad Laboratories, Inc.
12.5 Enzo Biochem, Inc.
12.6 Ekf Diagnostics Holdings, Inc.
12.7 Meso Scale Diagnostics, Llc.
12.8 Biosims Technologies Sas
12.9 Cisbio Bioassays
12.1 Signosis, Inc.
*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 146)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Other Developments
13.4 Knowledge Store: Marketsandmarkets Subscription Portal
13.5 Introducing Rt: Real-Time Market Intelligence
13.6 Available Customizations
13.7 Related Reports
13.8 Author Details
List of Tables (179)
Table 1 List of Fda-Approved Biomarkers for Different Types of Cancer
Table 2 Biomarkers Market Size, By Product, 20142021 (Usd Billion)
Table 3 Biomarker Consumables Market Size, By Region, 20142021 (USD Billion)
Table 4 North America: Biomarker Consumables Market Size, By Country, 20142021 (USD Billion)
Table 5 Europe: Biomarker Consumables Market Size, By Country, 20142021 (USD Billion)
Table 6 Asia: Biomarker Consumables Market Size, By Country, 20142021 (USD Billion)
Table 7 Row: Biomarker Consumables Market Size, By Country, 20142021 (USD Billion)
Table 8 Biomarker Services Market Size, By Region, 20142021 (USD Billion)
Table 9 North America: Biomarker Services Market Size, By Country, 20142021 (USD Billion)
Table 10 Europe: Biomarker Services Market Size, By Country, 20142021 (USD Billion)
Table 11 Asia: Biomarker Services Market Size, By Country, 20142021 (USD Billion)
Table 12 Row: Biomarker Services Market Size, By Country, 20142021 (USD Billion)
Table 13 Biomarker Software Market Size, By Region, 20142021 (USD Billion)
Table 14 North America: Biomarker Software Market Size, By Country, 20142021 (USD Billion)
Table 15 Europe: Biomarker Software Market Size, By Country, 20142021 (USD Billion)
Table 16 Asia: Biomarker Software Market Size, By Country, 20142021 (USD Billion)
Table 17 Row: Biomarker Software Market Size, By Country, 20142021 (USD Billion)
Table 18 Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 19 Safety Biomarkers Market Size, By Region, 20142021 (USD Billion)
Table 20 North America: Safety Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 21 Europe: Safety Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 22 Asia: Safety Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 23 Row: Safety Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 24 Efficacy Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 25 Efficacy Biomarkers Market Size, By Region, 20142021 (USD Billion)
Table 26 North America: Efficacy Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 27 Europe: Efficacy Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 28 Asia: Efficacy Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 29 Row: Efficacy Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 30 Predictive Biomarkers Market Size, By Region, 20142021 (USD Billion)
Table 31 North America: Predictive Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 32 Surrogate Biomarkers Market Size, By Region, 20142021 (USD Billion)
Table 33 North America: Surrogate Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 34 Pharmacodynamic Biomarkers Market Size, By Region, 20142021 (USD Billion)
Table 35 North America: Pharmacodynamic Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 36 Prognostic Biomarkers Market Size, By Region, 20142021 (USD Billion)
Table 37 North America: Prognostic Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 38 Validation Biomarkers Market Size, By Region, 20142021 (USD Billion)
Table 39 North America: Validation Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 40 Asia: Validation Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 41 Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 42 Biomarkers Market Size for Diagnostics Development, By Region, 20142021 (USD Billion)
Table 43 North America: Biomarkers Market Size for Diagnostics Development, By Country, 20142021 (USD Billion)
Table 44 Europe: Biomarkers Market Size for Diagnostics Development, By Country, 20142021 (USD Billion)
Table 45 Asia: Biomarkers Market Size for Diagnostics Development, By Country, 20142021 (USD Billion)
Table 46 Row: Biomarkers Market Size for Diagnostics Development, By Country, 20142021 (USD Billion)
Table 47 Biomarkers Market Size for Drug Discovery and Development, By Region, 20142021 (USD Billion)
Table 48 North America: Biomarkers Market Size for Drug Discovery and Development, By Country, 20142021 (USD Billion)
Table 49 Europe: Biomarkers Market Size for Drug Discovery and Development, By Country, 20142021 (USD Billion)
Table 50 Asia: Biomarkers Market Size for Drug Discovery and Development, By Country, 20142021 (USD Billion)
Table 51 Row: Biomarkers Market Size for Drug Discovery and Development, By Country, 20142021 (USD Billion)
Table 52 Biomarkers Market Size for Personalized Medicine, By Region, 20142021 (USD Billion)
Table 53 North America: Biomarkers Market Size for Personalized Medicine, By Country, 20142021 (USD Billion)
Table 54 Europe: Biomarkers Market Size for Personalized Medicine, By Country, 20142021 (USD Billion)
Table 55 Asia: Biomarkers Market Size for Personalized Medicine, By Country, 20142021 (USD Billion)
Table 56 Row: Biomarkers Market Size for Personalized Medicine, By Country, 20142021 (USD Billion)
Table 57 Biomarkers Market Size for Disease Risk Assessment, By Region, 20142021 (USD Billion)
Table 58 North America: Biomarkers Market Size for Disease Risk Assessment, By Country, 20142021 (USD Billion)
Table 59 Europe: Biomarkers Market Size for Disease Risk Assessment, By Country, 20142021 (USD Billion)
Table 60 Asia: Biomarkers Market Size for Disease Risk Assessment, By Country, 20142021 (USD Billion)
Table 61 Row: Biomarkers Market Size for Disease Risk Assessment, By Country, 20142021 (USD Billion)
Table 62 Biomarkers Market Size for Other Applications, By Region, 20142021 (USD Billion)
Table 63 North America: Biomarkers Market Size for Other Applications, By Country, 20142021 (USD Billion)
Table 64 Europe: Biomarkers Market Size for Other Applications, By Country, 20142021 (USD Billion)
Table 65 Asia: Biomarkers Market Size for Other Applications, By Country, 20142021 (USD Million)
Table 66 Row: Biomarkers Market Size for Other Applications, By Country, 20142021 (USD Billion)
Table 67 Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 68 Key Cancer Biomarkers in Clinical Use
Table 69 Biomarkers Market Size for Cancer, By Region, 20142021 (USD Billion)
Table 70 North America: Biomarkers Market Size for Cancer, By Country, 20142021 (USD Billion)
Table 71 Europe: Biomarkers Market Size for Cancer, By Country, 20142021 (USD Billion)
Table 72 Asia: Biomarkers Market Size for Cancer, By Country, 20142021 (USD Billion)
Table 73 Row: Biomarkers Market Size for Cancer, By Country, 20142021 (USD Billion)
Table 74 Biomarkers for Cardiovascular Disorder
Table 75 Biomarkers Market Size for Cardiovascular Disorders, By Region, 20142021 (USD Billion)
Table 76 North America: Biomarkers Market Size for Cardiovascular Disorders, By Country, 20142021 (USD Billion)
Table 77 Europe: Biomarkers Market Size for Cardiovascular Disorders, By Region/Country, 20142021 (USD Billion)
Table 78 Asia: Biomarkers Market Size for Cardiovascular Disorders, By Region/Country, 20142021 (USD Billion)
Table 79 Row: Biomarkers Market Size for Cardiovascular Disorders, By Region/Country, 20142021 (USD Billion)
Table 80 Biomarkers Market Size for Neurological Disorders, By Region, 20142021 (USD Billion)
Table 81 North America: Biomarkers Market Size for Neurological Disorders, By Country, 20142021 (USD Billion)
Table 82 Europe: Biomarkers Market Size for Neurological Disorders, By Country, 20142021 (USD Billion)
Table 83 Asia: Biomarkers Market Size for Neurological Disorders, By Region/Country, 20142021 (USD Billion)
Table 84 Row: Biomarkers Market Size for Neurological Disorders, By Country, 20142021 (USD Billion)
Table 85 Biomarkers for Immunological Disorders
Table 86 Biomarkers Market Size for Immunological Disorders, By Region, 20142021 (USD Billion)
Table 87 North America: Biomarkers Market Size for Immunological Disorders, By Country, 20142021 (USD Billion)
Table 88 Europe: Biomarkers Market Size for Immunological Disorders, By Country, 20142021 (USD Billion)
Table 89 Asia: Biomarkers Market Size for Immunological Disorders, By Region/Country, 20142021 (USD Billion)
Table 90 Row: Biomarkers Market Size for Immunological Disorders, By Country, 20142021 (USD Billion)
Table 91 Biomarkers for Renal Disorders
Table 92 Biomarkers Market Size for Other Diseases, By Region, 20142021 (USD Billion)
Table 93 North America: Biomarkers Market Size for Other Diseases, By Country, 20142021 (USD Billion)
Table 94 Europe: Biomarkers Market Size for Other Diseases, By Country, 20142021 (USD Billion)
Table 95 Asia: Biomarkers Market Size for Other Diseases, By Country, 20142021 (USD Billion)
Table 96 Row: Biomarkers Market Size for Other Diseases, By Country, 20142021 (USD Billion)
Table 97 Biomarkers Market Size, By Region, 20142021 (USD Billion)
Table 98 North America: Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 99 North America: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 100 North America: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 101 North America: Efficacy Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 102 North America: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 103 North America: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 104 U.S.: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 105 U.S.: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 106 U.S.: Efficacy Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 707 U.S.: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 108 U.S.: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 109 Canada: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 110 Canada: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 111 Canada: Efficacy Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 112 Canada: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 113 Canada: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 114 Europe: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 115 Europe: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 116 Europe: Efficacy Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 117 Europe: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 118 Europe: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 119 Germany: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 120 Germany: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 121 Germany: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 122 Germany: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 123 Uk: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 124 Uk: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 125 Uk: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 126 Uk: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 127 France: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 128 France: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 129 France: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 130 France: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 131 Italy: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 132 Italy: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 133 Italy: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 134 Italy: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 135 Spain: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 136 Spain: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 137 Spain: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 138 Spain: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 139 Roe: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 140 Roe: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 141 Roe: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 142 Roe: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 143 Asia: Biomarkers Market Size, By Country, 20142021 (USD Billion)
Table 144 Asia: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 145 Asia: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 146 Asia: Efficacy Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 147 Asia: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 148 Asia: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 149 China: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 150 China: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 151 China: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 152 China: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 153 Japan: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 154 Japan: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 155 Japan: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 156 Japan: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 157 Rest of Asia: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 158 Rest of Asia: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 159 Rest of Asia: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 160 Rest of Asia: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 161 Row: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 162 Row: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 163 Row: Efficacy Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 164 Row: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 165 Row: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 166 Latin America: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 167 Latin America: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 168 Latin America: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 169 Latin America: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 170 Middle East& Africa: Biomarkers Market Size, By Product, 20142021 (USD Billion)
Table 171 Middle East& Africa: Biomarkers Market Size, By Type, 20142021 (USD Billion)
Table 172 Middle East& Africa: Biomarkers Market Size, By Application, 20142021 (USD Billion)
Table 173 Middle East& Africa: Biomarkers Market Size, By Disease Indication, 20142021 (USD Billion)
Table 174 Battle for Market Share: Product Launch Was the Key Strategy Adopted By Market Players in Biomarkers Market Between 2014 and 2016
Table 175 Product Launches, 20142016
Table 176 Collaborations, Partnerships, and Agreements, 20142016
Table 177 Acquisitions, 20142016
Table 178 Other Developments, 20142016
Table 179 Rank of Companies in the Biomarkers Market, 2016
List of Figures (37)
Figure 1 Biomarkers Market Segmentation
Figure 2 Research Design
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 6 Data Triangulation Methodology
Figure 7 Biomarkers Market Size, By Product, 2016 Vs. 2021 (USD Billion)
Figure 8 Biomarkers Market Size, By Type, 2016 Vs. 2021 (USD Billion)
Figure 9 Biomarkers Market Size, By Application, 2016 Vs. 2021 (USD Billion)
Figure 10 Biomarkers Market Size, By Disease Indication, 2016 Vs. 2021 (USD Billion)
Figure 11 Biomarkers Market Size, By Region, 2016 Vs. 2021 (USD Billion)
Figure 12 Biomarkers Market To Register A High, Double-Digit Growth Rate During the Forecast Period
Figure 13 Consumables Segment To Account for the Largest Market Share in 2016
Figure 14 Safety Biomarkers Will Continue To Dominate the Biomarkers Market in 2021
Figure 15 Diagnostics Segment Accounted for the Largest Market Share in 2016
Figure 16 Cancer Segment Accounted for the Largest Market Share in 2016
Figure 17 Asia To Account for the Highest CAGR During the Forecast Period
Figure 18 Asian Market Shows Lucrative Growth Opportunities
Figure 19 Biomarkers Market: Drivers, Restraints, Opportunities, and Challenges
Figure 20 Increasing R&D Investments Boosting Growth in the Biomarkers Market
Figure 21 Increasing Number of New Cancer Cases Worldwide (2012 Vs. 2015 Vs. 2020)
Figure 22 Consumables Segment Accounted for the Largest Share of the Biomarkers Market in 2016
Figure 23 Safety Biomarkers Segment To Dominate the Market During the Forecast Period
Figure 24 Diagnostics Application Segment To Account for the Largest Share of the Biomarkers Market in 2016
Figure 25 Cancer To Form the Largest Segment in the Biomarkers Market in 2016
Figure 26 Biomarkers Market: Geographic Snapshot
Figure 27 Asia: an Attractive Destination for All Application Categories
Figure 28 North America: Market Snapshot
Figure 29 Asia: Market Snapshot
Figure 30 Product Launch, the Most Adopted Growth Strategy From 2014 To 2016
Figure 31 Geographic Revenue Mix of the Top 5 Market Players (2015)
Figure 32 Company Snapshot: Qiagen N.V. (2015)
Figure 33 Company Snapshot: Perkinelmer, Inc. (2015)
Figure 34 Company Snapshot: Merck Millipore (2015)
Figure 35 Company Snapshot: Bio-Rad Laboratories, Inc. (2015)
Figure 36 Company Snapshot: Enzo Biochem, Inc. (2016)
Figure 37 Company Snapshot: Ekf Diagnostics Holdings, Inc. (2015)
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Biomarkers Market